07:03 AM EDT, 07/12/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) Ozempic may reduce the risk of dementia and other neurological issues compared to older antidiabetic medications like sitagliptin and glipizide, according to a study by the University of Oxford and published by The Lancet's eClinicalMedicine journal on Wednesday.

After a year on Ozempic, patients showed a lower risk of dementia, cognitive deficits, and risk of smoking compared with those on older drugs, according to the study.

The study, which assessed the neurological and psychiatric risks associated with using Ozempic, was based on medical records of over 100,000 US patients.

Price: 141.41, Change: +1.62, Percent Change: +1.16